Doctor Remains Cancer-Free After Incurable Brain Tumor Diagnosis, Thanks to His Own Treatment
By waterbaby
Australian doctor Professor Richard Scolyer has announced that he remains cancer-free one year after undergoing a pioneering treatment for glioblastoma (GBM), one of the most aggressive and deadly forms of brain cancer.
The 57-year-old professor's latest MRI scan showed no recurrence of the tumor, marking a significant milestone in the fight against GBM
Credit: Professor Richard Scolyer AO / @ProfRScolyerMIA
Dr. Scolyer, renowned for his groundbreaking research on melanoma, was diagnosed with a particularly aggressive subtype of GBM in June last year following a seizure while in Poland. GBM typically has a dire prognosis, with most patients surviving less than a year after diagnosis. However, Scolyer's experience has defied these odds, offering new hope to patients worldwide.
Sharing his joy on social media, Scolyer tweeted, "I had brain #MRI scan last Thursday looking for recurrent #glioblastoma (&/or treatment complications). I found out yesterday that there is still no sign of recurrence. I couldn’t be happier!"
https://twitter.com/ProfRScolyerMIA/status/1790144527824789739
Scolyer's treatment was a world-first, involving pre-surgery combination immunotherapy. Drawing on his extensive expertise and research in melanoma, he applied this innovative approach to his own condition. This pioneering treatment strategy aimed to stimulate the immune system to combat the cancer more efficiently. "We've demonstrated that it's possible to activate the immune system effectively. This represents a fundamental initial stride in reshaping the field and the approach to drug exploration in brain cancer," Scolyer explained to Sky News.
You are currently reading about Doctor Remains Cancer-Free After Incurable Brain Tumor Diagnosis, Thanks to His Own Treatment. If you've found this helpful, please share Doctor Remains Cancer-Free After Incurable Brain Tumor Diagnosis, Thanks to His Own Treatment on your favorite social media site, such as Facebook, Twitter, or Google+
